On this page
📌 FDA & Cosmetics Safety Hub: browse all 7 guides »
Hearing aids are medical devices; personal sound amplification products (PSAPs) serve a different intended purpose. FDA describes PSAPs as amplifying sounds in certain environments for listeners without hearing impairment, not compensating for hearing impairment. Shared amplification therefore does not establish equivalent intended use or individual suitability. See FDA’s descriptions of hearing aids and PSAPs.
If both amplify sound, why distinguish them?
Separate two questions: what does the product do to sound, and who is it intended for and for what purpose? Amplification answers the first, not the second. The same split applies to lenses that only change appearance — they still need a prescription and proper fitting: see Decorative Contact Lenses in the U.S.: Why Appearance-Only Lenses Still Need a Prescription and Proper Fit. This is an editorial reading framework based on FDA’s distinction—not a device-selection assessment. Similar appearance cannot resolve the unanswered purpose or suitability questions. FDA’s intended-use distinction.
What intended use does FDA describe for PSAPs?
FDA identifies PSAPs as electronic products regulated under its Electronic Product Radiation Control Program, not medical devices such as hearing aids. Being outside the medical-device category therefore does not mean being outside FDA oversight. FDA’s PSAP explanation.
When reading about a product, seek an explicit statement of its intended listener and listening purpose. Does the description address hearing impairment or listening in particular environments? If that information is unclear, leave the intended-use question unresolved rather than filling the gap from the product’s shape or amplification function.
What does FDA establish about hearing aids?
FDA describes hearing aids as medical devices worn behind or in the ear that make sounds louder. They generally do not restore normal hearing levels or quality. FDA’s hearing-aid explanation.
Keep that general description separate from a conclusion about a particular model. Identifying a product’s category does not answer how well it would work for you, and making sound louder is not the same promise as restoring normal hearing.
Two questions to ask of any product page
This article’s test fits on two lines. First question: who is the intended listener? Second: for what purpose? The Food and Drug Administration identifies personal sound amplification products as amplifying sounds in certain environments for listeners without hearing impairment, not compensating for hearing impairment. A product page that only talks about amplification answers neither question. When reading about a product, seek an explicit statement of its intended listener and listening purpose. If that information is unclear, leave the intended-use question unresolved rather than filling the gap from the product’s shape or amplification function.
Why “louder” is not a promise
The Food and Drug Administration describes hearing aids as medical devices worn behind or in the ear that make sounds louder. It also says they generally do not restore normal hearing levels or quality. Louder and normal are two different promises, and the article is careful to keep them apart. The same split applies in reverse to personal sound amplification products: amplifying sounds in certain environments is not the same as compensating for hearing impairment. Keep the category, the function and the promise in three separate columns, and the product page gets much easier to read — and much harder to misread.
What cannot be concluded about a particular product or reader?
Neither supplied excerpt evaluates a named product or individual. A useful next step is to bring the product’s stated audience and purpose to a discussion with a hearing-care professional, keeping those statements separate from questions about your own needs. The category distinction helps frame that discussion; it does not settle individual suitability. This article provides no product ranking or recommendation.
Source context: supplied FDA excerpts captured 25 October 2026, not a live availability check. The first capture is truncated; omitted details are not assumed. Changes to intended-use descriptions or regulatory classifications require refreshed evidence.


